STAT

JANUARY 10, 2024

The findings are already influencing clinical practice: It’s becoming standard for patients in the National Health Service with those tumors — including types of brain cancers, sarcomas, and ovarian cancers — to get their tumors sequenced. In a paper published Thursday morning in the U.K.,

Patient Care 132

Patient Care 132

Pharmacy Times

DECEMBER 16, 2022

Clinical oncology pharmacist Amy Indorf, PharmD, BCOP, discusses her presentation on the role of PARP inhibitors for ovarian cancer.

123

123

STAT

DECEMBER 6, 2023

Facing the prospect of declining sales from two of its best-selling drugs, the company also acquired Immunogen and its ovarian cancer treatment for $10 billion last Thursday. The deal marks the second billion-dollar acquisition by AbbVie in under a week.

128

128

European Pharmaceutical Review

NOVEMBER 22, 2023

The small molecule treatment is indicated as a first-line maintenance treatment for individuals with advanced ovarian cancer regardless of their BRCA mutation status, who have responded to first-line platinum-based chemotherapy. ” The EC based its approval the Phase III ATHENA-MONO study results.

Chemotherapy 89

Chemotherapy Labelling 89

Pharmaceutical Technology

APRIL 18, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Ovarian Cancer.

40

40

Pharmaceutical Technology

APRIL 17, 2024

SLATE-001 is under clinical development by Gritstone Bio and currently in Phase I for Metastatic Ovarian Cancer.

40

40

STAT

SEPTEMBER 25, 2023

For months, oncologist Kristen Rice found herself scrambling for cisplatin and carboplatin, two key chemotherapies used for many different cancers including ovarian, bladder, and lung cancer. Pharmacy technicians would order more drugs each day to keep the clinic running until, one day, they couldn’t.

Chemotherapy 133

Chemotherapy Hospitals 133

Pharmaceutical Commerce

JANUARY 23, 2024

NK010, which showed promising anti-tumor activity and safety in preclinical studies, will be evaluated in a Phase I clinical trial for ovarian cancer.

FDA 52

FDA 52

Pharmaceutical Technology

NOVEMBER 14, 2022

positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Elahere obtained the approval based on the findings on objective response rate (ORR) and duration of response (DOR) reported in the SORAYA clinical trial. positive platinum-resistant ovarian cancer.

FDA 98

FDA 98

Pharmaceutical Technology

JANUARY 22, 2024

SGN-1 is under clinical development by Guangzhou Sinogen Pharmaceutical and currently in Phase II for Metastatic Ovarian Cancer.

52

52

pharmaphorum

OCTOBER 27, 2022

Last month, pharmaphorum had the chance to speak with Dr Isabelle Ray-Coquard, professor of medical oncology (specialism sarcomas and GISTs) at the Centre Léon Bérard (CLB), a hospital 100% dedicated to cancer care and research. HRD (homologous recombination deficiency) is an important biomarker of the most advanced stages of ovarian cancer.

Chemotherapy 94

Chemotherapy Hospitals FDA 94

STAT

NOVEMBER 30, 2023

… AbbVie will pay $10 billion for Immunogen, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology , STAT writes. Under Food and Drug Administration approval for advanced ovarian cancer in 2022. We hope you find these useful and have a smashing day.

Compounding 107

Compounding Compounding Pharmacies Chemotherapy FDA 107

Pharmacy Times

JUNE 5, 2023

Positive findings in patients with advanced high-grade epithelial ovarian cancer were presented during an oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting.

65

65

pharmaphorum

AUGUST 13, 2021

Six years ago, research scientist Inbal Zafir-Lavie tragically lost her 38-year-old sister Hava Zafir to colorectal cancer. Due to her young age, doctors had been unable to detect the cancer through screening and by the time of diagnosis, it was too late. The loss of her sister had a profound effect on Inbal. Early detection.

105

105

Pharmafile

DECEMBER 1, 2023

AbbVie and ImmunoGen have announced that AbbVie will acquire ImmunoGen and its lead cancer therapy Elahere (mirvetuximab soratansine-gynx), a first in class antibody-drug conjugate (ADC) approved for the treatment of platinum-resistance ovarian cancer (PROC).

59

59

Pharmaceutical Technology

DECEMBER 25, 2023

HCW-9218 is under clinical development by HCW Biologics and currently in Phase I for Ovarian Cancer.

52

52

Pharmaceutical Technology

DECEMBER 26, 2023

KSQ-4279 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Ovarian Cancer.

53

53

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Ovarian Cancer.

40

40

Pharmaceutical Technology

JANUARY 4, 2024

TAC-101 is under clinical development by Triumvira Immunologics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase…

40

40

Roots Analysis

FEBRUARY 29, 2024

Sutro Biopharma, a California based, clinical-stage company, announced initial safety data in ovarian cancer patients from its ongoing phase I study ( NCT03748186 ) of STRO-002. The data are being presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019. Sutro Biopharma, Inc.,

40

40

Pharmaceutical Technology

APRIL 14, 2023

Clinical-stage biopharmaceutical company TORL BioTherapeutics has raised $158m in a Series B financing round for advancing the development of new biologics for cancer treatment. TORL BioTherapeutics is a newly formed, US-based company focused on the development of novel antibody-based therapeutics for cancer patients.

Compounding 105

Compounding 105

Pharmaceutical Technology

MAY 1, 2023

Under the deal terms, Shunxi will have licence to develop, manufacture, and commercialise CTH-004 to treat several solid tumours including ovarian cancer in Greater China, including Hong Kong, Taiwan, Mainland China, and Macao. In animal models of ovarian cancer, it demonstrated promising results.

52

52

Pharmaceutical Technology

DECEMBER 21, 2023

Luveltamab tazevibulin is under clinical development by Sutro Biopharma and currently in Phase I for Epithelial Ovarian Cancer.

40

40

Pharmaceutical Technology

DECEMBER 26, 2023

Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Epithelial Ovarian Cancer.

40

40

Pharmaceutical Technology

JANUARY 4, 2024

SH-105 is under clinical development by Shorla Oncology and currently in Pre-Registration for Ovarian Cancer.

40

40

Pharmaceutical Technology

DECEMBER 21, 2023

SGN-1 is under clinical development by Guangzhou Sinogen Pharmaceutical and currently in Phase II for Ovarian Cancer.

52

52

Pharmafile

APRIL 5, 2023

This combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy plus bevacizumab. The drug combination was assessed for newly diagnosed patients with advanced high-grade epithelial ovarian cancer without tumour BRCA mutations.

Chemotherapy 72

Chemotherapy Communication 72

Pharmaceutical Technology

DECEMBER 22, 2023

IDE-161 is under clinical development by Ideaya Biosciences and currently in Phase II for Metastatic Ovarian Cancer.

52

52

Pharmaceutical Technology

DECEMBER 21, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase II for Epithelial Ovarian Cancer.

40

40

Pharmaceutical Technology

DECEMBER 5, 2023

TCR-T Library is under clinical development by Alaunos Therapeutics and currently in Phase II for Ovarian Cancer.

40

40

Pharmaceutical Technology

APRIL 4, 2023

The collaboration will see the expansion of the investigative agent’s development, including activity in models of ovarian and other cancer types. Panbela claimed that ivospemin demonstrated signs of tumour growth inhibition in clinical trials involving patients with metastatic pancreatic cancer.

Chemotherapy 59

Chemotherapy Compounding FDA 59

Pharmaceutical Technology

DECEMBER 22, 2023

Dresbuxelimab is under clinical development by Akeso and currently in Phase I for Ovarian Cancer.

40

40

Pharmaceutical Technology

DECEMBER 4, 2023

XmAb-808 is under clinical development by Xencor and currently in Phase I for Epithelial Ovarian Cancer.

40

40

Pharmaceutical Technology

NOVEMBER 16, 2023

BT-7480 is under clinical development by Bicycle Therapeutics and currently in Phase II for Ovarian Cancer.

52

52

Pharmaceutical Technology

NOVEMBER 16, 2023

BT-7480 is under clinical development by Bicycle Therapeutics and currently in Phase II for Ovarian Cancer.

40

40

Pharmaceutical Technology

NOVEMBER 3, 2023

LOAd-703 is under clinical development by Lokon Pharma and currently in Phase II for Epithelial Ovarian Cancer.

40

40

Pharmaceutical Technology

OCTOBER 27, 2023

BGB-10188 is under clinical development by BeiGene and currently in Phase II for Epithelial Ovarian Cancer.

40

40